Compare BIIB & MLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | MLM |
|---|---|---|
| Founded | 1978 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9B | 32.9B |
| IPO Year | 1996 | 1996 |
| Metric | BIIB | MLM |
|---|---|---|
| Price | $216.64 | $526.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 14 |
| Target Price | $206.83 | ★ $689.36 |
| AVG Volume (30 Days) | ★ 923.8K | 603.1K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.15 | ★ 29.27 |
| Revenue | ★ $9,890,600,000.00 | $6,150,000,000.00 |
| Revenue This Year | N/A | $13.76 |
| Revenue Next Year | N/A | $7.98 |
| P/E Ratio | $103.05 | ★ $18.30 |
| Revenue Growth | ★ 2.22 | N/A |
| 52 Week Low | $131.54 | $522.19 |
| 52 Week High | $222.15 | $710.97 |
| Indicator | BIIB | MLM |
|---|---|---|
| Relative Strength Index (RSI) | 58.71 | 40.59 |
| Support Level | $184.50 | $524.43 |
| Resistance Level | $218.03 | $633.96 |
| Average True Range (ATR) | 5.45 | 13.06 |
| MACD | 1.09 | -1.08 |
| Stochastic Oscillator | 72.80 | 10.36 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.